(Q40175982)

English

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases

scientific article published on 30 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

electroporation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

An M T Van Nuffel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Sofie Wilgenhof

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jurgen Corthals

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Daphné Benteyn

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Carlo Heirman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Aude Bonehill

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Kris Thielemans

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

30 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

64

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

381-388

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548092%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Human T cell responses against melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Cancer immunotherapy via dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1642-8

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40175982&oldid=2203472103"